Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioInvent International AB ( (SE:BINV) ) has provided an update.
BioInvent International AB has announced promising results from its Phase 2a study of BI-1808, a monotherapy for cutaneous T-cell lymphoma (CTCL), showing a 100% disease control rate and significant immune activation. The study, which will be presented at the EHA 2025 congress, highlights the potential of BI-1808 as an immune-modulating therapy with a favorable safety profile, marking a significant milestone in BioInvent’s mission to develop transformative cancer therapies.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on the discovery and development of novel, first-in-class antibodies for cancer immunotherapy. The company operates in the field of hematological cancer and solid tumors, with five drug candidates in six ongoing clinical programs. BioInvent’s proprietary F.I.R.S.T technology platform is instrumental in identifying targets and antibodies, fueling its clinical development pipeline and offering licensing and partnering opportunities.
Average Trading Volume: 110,683
Current Market Cap: SEK2.4B
See more data about BINV stock on TipRanks’ Stock Analysis page.